Citations

Clear

3641 citation(s) found for "South, AP".

Caregiver-Rated Inappropriate Speech and Post-cTBS Motor Cortical Facilitation in Autism: A Pilot Biomarker Study
Smith, Joshua R. , Bonnée, Maria , Atwood, Rowan, Lewis, B.D., Lim, Seri , Baldwin, Isaac , Liu, Jinyuan , Cascio, Carissa J. , Joshi, Gagan , Croarkin, Paul E. , Marler, Sarah , Lewis, Brianna, Wu, Hao , Smith, Joshua Ryan , Lim, Seri , Baldwin, Isaac , Liu, Jinyuan , Cascio, Carissa , Joshi, Gagan , Croarkin, Paul E

Mayo Clinic

No container title available | September 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.10.26362749 | PMID 42819007 Get It

Transcranial magnetic stimulation can provide noninvasive measures of cortical excitability and plasticity, but relationships between these measures and clinically observable features of autism are not fully characterized. Nineteen autistic participants aged 15 to 40 years were included in the analysis of a left primary motor cortex continuous theta-burst stimulation (cTBS) biomarker protocol. Motor evoked potentials were measured at baseline and at seven assessments from 5 to 60 min after stimulation. Linear mixed-effects models evaluated whether clinical measures moderated the post-stimulation motor evoked potential log-response ratio over time. Aberrant Behavior Checklist (ABC) and Attenuated Behavior Questionnaire (ABQ) analyses were restricted to the same 15 participants with caregiver-informant assessments. Catatonia severity, social impairment, ABQ Motor Total, ABQ Total, and cognitive ability did not significantly moderate the post-stimulation response. ABC Inappropriate Speech was associated with progressively greater post-stimulation facilitation (standardized Time-by-Inappropriate Speech interaction: beta = +0.688, SE = 0.210, 95% CI +0.276 to +1.099; Holm-adjusted P = .008 across eight informant-rated models). Two individual speech-related items ("Talks excessively" and "Talks to self loudly") survived false-discovery-rate correction. An exploratory eight-item ABC phenotype showed a large descriptive in-sample association (beta = +0.904, SE = 0.200, P less than .001) and directionally positive held-out performance. However, full-pipeline permutation tests were nonsignificant for both Pearson (r = .357, two-sided empirical P = .360) and Spearman correlations (rho = .446, two-sided empirical P = .261). Caregiver-rated inappropriate speech may be associated with altered post-cTBS motor cortical facilitation in autism. The candidate phenotype remains hypothesis-generating and requires independent validation.
Building trauma-informed physical therapists: a mixed-methods evaluation of a multimodal training module in hybrid DPT education
Parr, Rebecca E. , Richardson, Michael V., Anderson, Kristen, Anderson, Kristen

Mayo Clinic

Physiotherapy Theory and Practice | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-16

10.1080/09593985.2026.2730589 | PMID 42708499 Get It

MicroRNA Control of Hepatocyte–Stromal Crosstalk in the Early Premalignant Microenvironment of HBV-Associated HCC
Sartorius, Kurt , Kramvis, Anna , Chuturgoon, Anil A. , Chuturgoon, Anil

Mayo Clinic

International Journal of Molecular Sciences | August 24, 2026 | Volume: 27 | Issue: 17 | Pages: 7581

10.3390/ijms27177581 | PMID 42737483 Get It

Chronic hepatitis B virus (CHB) infection remains a major cause of hepatocellular carcinoma (HCC), yet the premalignant microenvironment that links to HBV-associated HCC (HBV-HCC) is still poorly defined. This review synthesizes evidence that HBV-infected hepatocytes function as signaling hubs that, through microRNA (miRNA)-regulated crosstalk with Kupffer cells, liver sinusoidal endothelial cells, hepatic stellate cells and cancer-associated fibroblasts (CAFs), progressively remodel the liver from an antiviral tissue into a premalignant and early tumor microenvironment. Across the HBV-HCC continuum, a core set of dysregulated miRNAs, including miR-21, miR-29a/b, miR-122, miR-146a, miR-155, miR-200a, miR-126, miR-210 and the miR-130/301 family, coordinates transition from innate antiviral responses to HSC activation, extracellular matrix deposition, mechanotransduction, angiogenesis, chronic inflammation and cancer-associated CAF programing. By mapping these stage-specific miRNA networks onto acute infection, CHB, early fibrogenesis, advanced fibrosis and CAF-rich dysplastic states, the review reframes HBV-HCC pathogenesis as a sequence of miRNA-guided hepatocyte–stromal states rather than a purely hepatocyte-intrinsic process. This perspective suggests that composite, cell-type-resolved miRNA signatures in serum or liver tissue could serve as biomarkers for identifying CHB patients who are entering a premalignant microenvironment before conventional surveillance markers become abnormal. It further highlights miRNA hubs that couple antiviral, fibrogenic, angiogenic and CAF-associated signaling as potential therapeutic targets for reprograming the HBV-driven premalignant microenvironment, with the long-term goal of intercepting HBV-HCC development at earlier, microenvironmentally defined stages.
Implant-Grade Neural Sensing with Artifact-Resilient Computational Intelligence Preserves Spatial Fidelity of HFO Biomarkers in Epilepsy
Besheli, Behrang Fazli , Ayyoubi, Amir Hossein , Swamy, Chandra Prakash , Okkabaz, Jhan L., Miller, Kai J., Marsh, W. Richard , Gregg, Nicholas M., Worrell, Gregory A., Ince, Nuri F., Okkabaz, Jhan Luke , Gompel, Jamie J. Van , Miller, Kai J., Gregg, Nicholas M. , Worrell, Gregory A. , Ince, Nuri F.

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10657493/v1 | PMID 42688011 Get It

Abstract High-frequency oscillations (HFOs) are clinically established biomarkers of epileptogenic tissue, yet their translation from hospital-based recording systems to implantable neural interfaces remains a major barrier to their utilization in adaptive neuromodulation in epilepsy. Here, we established a bedside translational framework using a benchtop implementation of a wireless implantable neural interface (Brain Interchange, BIC) to evaluate whether clinically meaningful HFO can be preserved under implant-grade sensing constraints. Ten patients with drug resistant epilepsy underwent simultaneous 24-hour intracranial EEG recordings using synchronized BICs and a clinical-grade amplifier. A sensitive detector identified candidate HFOs, while sparse signal processing and machine learning methods removed artifact related pseudo-HFOs. Despite its lower sampling rate, narrower analog bandwidth, and higher noise floor, the integrated sensing and computational intelligence framework preserved approximately 82% of clinical amplifier HFOs and maintained nearly identical spatial distribution of pathological activity. After pseudo-HFO elimination, BIC derived HFOs localized the seizure onset zone with 84% sensitivity and 90% specificity, comparable to the clinical amplifier despite lower fast ripple detection. These findings demonstrate that implant-grade neural sensing, when integrated with artifact resilient computational intelligence, can preserve clinically relevant HFO biomarkers and their spatial fidelity without reproducing every individual electrophysiological event. More broadly, this work establishes a translational framework for chronic tracking of evolving epileptogenic networks and future biomarker-guided adaptive neuromodulation.
Variability in recommending epilepsy surgery across Level IV epilepsy centers in the United States
Caraway, Avery R. , McNamara, Nancy A. , Knox, Andrew , Samanta, Debopam , Wolf, Steven M. , Novotny, Edward J., Ostendorf, Adam P. , Eschbach, Krista , Depositario‐Cabacar, Dewi F. , Pichon, Pilar, Auguste, Kurtis I., Bernardo, Danilo , Singh, Rani K., Ciliberto, Michael A., Reddy, Shilpa B., Arredondo, Kristen H. , Marashly, Ahmad , Galan, Fernando N., Armstrong, Dallas M., Wagner, Janelle L. , Wong-Kisiel, Lily C. , Bolton, Jeffrey B., Lin, Jenny, Coryell, J., Perry, Μ. Scott , Group, the rest of the PERC Surgery Special Interest, Galán, Fernando , Knox, Andrew T , Eschbach, Krista , Bernardo, Danilo , Grinspan, Zachary , Abel, Taylor J , Perry, Michael Scott , Galan, Fernando N , Wolf, Steven , McNamara, Nancy A., Novotny, Edward J. , Depositario‐Cabacar, Dewi, Karakas, Cemal , Auguste, Kurtis I. , Javarayee, Pradeep , Singh, Rani K., Ciliberto, Michael A. , Reddy, Shilpa B. , Armstrong, Dallas , Wong‐Kisiel, Lily C. , Bolton, Jeffrey , Grinspan, Zachary M. , Abel, Taylor J. , Coryell, Jason

Mayo Clinic

Epilepsia | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70440 | PMID 42621761 Get It

Abstract Objective Surgery is an effective, yet underutilized treatment for children with drug‐resistant epilepsy. Although predictors of surgical outcomes are well described, the decision to recommend surgery varies by institution. We aim to evaluate the rates of not recommending surgery, identify associated patient characteristics, and quantify variability across centers. Methods We queried the Pediatric Epilepsy Research Consortium Surgery database, a prospective multicenter cohort of children (0–18 years) undergoing initial evaluation for epilepsy surgery. Patients with documented surgical decisions were included. Demographic, clinical, and presurgical evaluation variables were compared by surgical recommendation status. Logistic regression identified factors associated with not recommending surgery. Mixed‐effects models quantified between‐center variability. Results Among 2480 patients across 29 centers, 532 (21%) were not recommended epilepsy surgery (median center rate 17%, interquartile range [IQR] 10%–28%). After accounting for patient characteristics associated with surgical candidacy, substantial variation in decision‐making remained across centers, with a median twofold difference in the odds of not recommending surgery between otherwise similar patients evaluated at different institutions (Median Odds Ratio = 2.25; Intraclass Correlation Coefficient = .18). The clinical characteristics most strongly associated with not recommending surgery included monthly or less frequent seizures (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.75–2.69), non‐structural etiology (OR 2.02, 95% CI 1.56–2.61), and taking ≤2 anti‐seizure medications (ASMs) (OR 1.67, 95% CI 1.34–2.08, all p 's < .01). These characteristics showed minimal clustering across centers (ICCs < .05). Significance One in five children evaluated for epilepsy surgery are not recommended to pursue surgical treatment. Although clinical factors influence decision‐making, they do not explain the substantial variation in recommendations across pediatric epilepsy centers. Similar children evaluated at different institutions had significant differences in the odds of not being recommended surgery, suggesting that institutional decision‐making contributes importantly to surgical candidacy.
American Society of Hematology 2026 Guidelines for Immune Thrombocytopenia (ITP): Initial and Second-Line Therapy in Adults with Primary ITP
Cuker, Adam, Terrell, Deirdra R. , Sowdagar, Honieh, Arnold, Donald M. , Audia, Sylvain , Bussel, James B. , González‐López, Tomás José , Masias, Camila , McCrae, Keith R. , Panch, Sandhya , Shah, Surbhi, Shy, Brenda G, Vandevelde, Jessica , Grace, Rachael F , McCrae, Keith R , Mitrovic, Mirjana , Neunert, Cindy E. , Panch, Sandhya Ramanathan , Cines, Douglas B , Vesely, Sara K , Arnold, Donald M , Terrell, Deirdra R , Cuker, Adam , González‐López, Tomás José , Grace, Rachael F. , VandeVelde, Jessica

Mayo Clinic

Blood Advances | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021269 | PMID 42617047 Get It

Background: Since publication of the American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia (ITP), new clinical trials have been completed and new treatments have become available. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) are a focused update of the 2019 ASH ITP guidelines, centering on treatment of adults with primary ITP. Methods: ASH formed a multidisciplinary guideline panel including two patient representatives that was balanced to minimize potential bias from conflicts of interest. The University of Oklahoma supported the guideline development process, including updating or performing systematic evidence reviews (up to July 19, 2025). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and identification of areas with new data or where application of new methods would be of benefit. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks and the GRADE framework for multiple comparisons, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on recommendations in adults with primary ITP regarding initial therapy and second-line treatment in patients who failed first-line corticosteroids. The panel also issued good practice statements on thrombopoietic agent switching and splenectomy. Conclusions: Novel recommendations of these guidelines include: (1) initial therapy with a combination of rituximab plus corticosteroids or a thrombopoietic agent plus corticosteroids rather than corticosteroids alone (conditional recommendation) and (2) a thrombopoietic agent (strong recommendation) or rituximab (conditional recommendation) for patients who failed first-line corticosteroids.
Moving beyond spike detection: High frequency‐driven masking improves seizure onset zone localization in intracranial electroencephalography
Ayyoubi, Amir Hossein , Besheli, Behrang Fazli , Hrtonová, Valentina , Okkabaz, Jhan L., Swamy, Chandra Prakash , Sha, Zhiyi , Gavvala, Jay R. , Gregg, Nicholas M. , Henry, Thomas R. , Pati, Sandipan , Marsh, W. Richard , Miller, Kai J. , Ince, Nuri F. , Fazli Besheli, Behrang , Okkabaz, Jhan Luke , Gavvala, Jay R , Gregg, Nicholas M , Karamursel, Sacit , Marsh, Richard , Van Gompel, Jamie J , Miller, Kai J , Kremen, Vaclav , Worrell, Gregory A , Ince, Nuri F , Pati, Sandipan Bankim Behari , Karamürsel, Saçit , Gompel, Jamie J. Van , Křemen, Václav , Worrell, Gregory A.

Mayo Clinic

Epilepsia | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70449 | PMID 42613958 Get It

Abstract Objective Interictal epileptiform spikes (IESs) are widely used biomarkers of epileptogenic tissue in presurgical epilepsy evaluation. However, their reliability for seizure onset zone (SOZ) localization in high‐density intracranial electroencephalography (iEEG) remains inconsistent. It is underexplored whether this variability reflects methodological differences across detection algorithms or a limitation of IESs as a biomarker. This study evaluates whether IES detection alone provides sufficient spatial specificity for accurate SOZ localization in iEEG. Methods We systematically benchmarked eight established IES detection algorithms using iEEG recordings from 35 patients with drug‐resistant focal epilepsy. To provide a clinically meaningful reference, algorithm performance was evaluated against the clinically defined SOZ. To refine detection outputs and move beyond only IES detection, we applied masking strategies to isolate informative IES subsets based on rate, amplitude, frequency, and co‐occurrence with high‐frequency oscillations (HFOs). Conceptually, masking acts as a spatial refinement strategy that progressively restricts diffuse IES activity to more focal, pathologically relevant event populations. Results Despite substantial variability in detection characteristics, SOZ localization performance (ratio of events originating from SOZ divided by total number of events) converged within a narrow range (.23–.51), suggesting that IESs exhibit an intrinsic ceiling in SOZ localization performance when used alone. Amplitude‐based masking yielded modest improvements, whereas frequency‐based masking reduced performance. In contrast, IES‐HFO co‐occurrence markedly improved localization, particularly when combined with rate‐based masking, achieving a median SOZ localization ratio of .89, exceeding IESs (.37) and HFOs (.63) evaluated independently. Significance These findings demonstrate that IES‐based SOZ localization may require moving beyond detection‐only approaches. The integration of informed, biomarker‐driven masking strategies provides a more robust framework for identifying the activity most relevant to the epileptogenic network and paves the way for future incorporation into the clinical decision‐making pipeline.
Validation of the Semi-Quantitative MRI (SQ-MRI) Score as a Biomarker for Non-Calcific Chronic Pancreatitis in a Multicenter Cohort
Tirkes, Temel, Chang, Stephanie T., Mawad, Kareem , Shah, Zarine K. , Venkatesh, Sudhakar K., Wachsman, Ashley, Li, Liang, Li, Shuang, Easler, Jeffrey, Fogel, Evan L. , Forsmark, Christopher E. , Hart, Phil A., Pandol, Stephen J., Park, Walter G., Topazian, Mark, Trikudanathan, Guru, Vege, Santhi Swaroop, Conwell, Darwin L., Yadav, Dhiraj, Tirkes, Temel , Dasyam, Anil K. , Spilseth, Benjamin , Takahashi, Naoki , Venkatesh, Sudhakar K. , Easler, Jeffrey J. , Forsmark, Chris E. , Hart, Phil A. , Pandol, Stephen J , Park, Walter G., Trikudanathan, Guru , Van Den Eeden, Stephen K , Vege, Santhi Swaroop , Conwell, Darwin L. , Yadav, Dhiraj

Mayo Clinic

No container title available | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10504233/v1 Get It

Abstract Purpose Validate the semiquantitative (SQ)-MRI score for chronic pancreatitis (CP) diagnosis in an independent, multicenter cohort. Methods We analyzed MRIs performed at baseline in 337 participants with acute (AP) or recurrent AP (RAP) and 67 with non-calcific chronic pancreatitis (NCCP) enrolled in the PROCEED study from 6/2017 to 3/2023. MRIs were performed at multiple clinical centers using site-specific clinical protocols and a variety of MRI vendors to evaluate the SQ-MRI score in a real-world setting. The SQ-MRI score was calculated using the T1 signal intensity ratio of the pancreas to the spleen (T1 score), arteriovenous enhancement ratio (AVR), and pancreatic body diameter (PBD). We adjusted for confounding by participant characteristics via propensity score weighting. Results Median AVR was higher in AP/RAP (1.18, IQR: 0.97–1.44) than in the NCCP group (1.03, IQR: 0.78–1.22, p = 0.007). Pancreatic body diameters were larger in AP/RAP than in the NCCP group − 7–14 mm (10% vs 25%), 14–20 mm (40% vs 54%), and > 20 mm (50% vs 21%), respectively ( p < 0.01). Median T1 score was higher in AP/RAP (1.18, IQR: 0.96–1.40) than in the NCCP group (1.04, IQR: 0.86–1.32, p = 0.10). Median SQ-MRI score in the AP/RAP group was significantly lower, 1.91 (IQR: 0.97, 2.95), than in the NCCP group, 2.74 (IQR: 2.04–4.03) ( p < 0.001). The propensity score-adjusted AUC for SQ-MRI to distinguish AP/RAP from NCCP was 0.64, which was higher than for individual parameters. Conclusion We have validated the SQ-MRI score in a multicenter cohort using an independent, real-world MRI dataset.
Maternal Exercise and Offspring Cardiac Regenerative Potential: Roles of Apelin and α-Ketoglutarate
Qin, Guanfeng , Li, Faqin , Shi, Haiwang , Li, Fan

Mayo Clinic

Biology | August 18, 2026 | Volume: 15 | Issue: 16 | Pages: 1422

10.3390/biology15161422 | PMID 42651726 Get It

Cardiovascular disease causes the largest number of deaths across the world. The weak regenerative ability of adult hearts originates from limited cell proliferation and polyploidization of postnatal cardiomyocytes, which severely hinders tissue repair after myocardial injury. Fetal development represents a critical window during which maternal physiological and metabolic status can shape long-term offspring cardiac structure and function. Maternal exercise represents a safe nonpharmacological prenatal intervention that confers long-term benefits to offspring health. Available evidence indicates that maternal exercise enhances placental apelin secretion and elevates α-ketoglutarate (α-KG) levels in fetal brown adipose tissue, liver, and skeletal muscle. The apelin and α-KG signaling cascade participates in epigenetic regulation and confers protective effects on offspring metabolic health. Independent animal experiments have further validated that supplementation with either apelin or α-KG alleviates myocardial infarction (MI)-induced cardiac injury in adult mice, with α-KG showing direct evidence of reactivating cardiomyocyte proliferation. Nevertheless, it remains poorly elucidated whether maternal exercise could modulate fetal cardiomyocyte proliferative capacity in offspring through apelin- or α-KG-associated signaling. This narrative review integrates current evidence and proposes a testable framework in which maternal exercise influences fetal cardiac growth and regenerative potential through placental, metabolic, and epigenetic signaling. Because direct evidence remains limited, this model should be regarded as a hypothesis that requires further experimental validation.
Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas
Minniti, Giuseppe, Brown, Paul D. , Vogelbaum, Michael A. , Ballman, Karla V. , Mercurio, Ann, Siegelin, Markus D., Tuohy, Kyle , Mansouri, Alireza , Simonelli, Matteo, DeStephano, David, Shuryak, Igor , Roy, Soumyajit , Hervey-Jumper, Shawn L., Horowitz, David P. , Sisti, Michael B. , Bruce, Jeffrey N. , Canoll, Peter, Neugut, Alfred I. , Iwamoto, Fabio M., Cheng, Simon K. , Kachnic, Lisa A. , Kinslow, Connor J , Brown, Paul D , Vogelbaum, Michael A , Ballman, Karla , Mercurio, Ann , Tuohy, Kyle , Mansouri, Alireza , Touat, Mehdi , Dehais, Caroline , Dipasquale, Angelo , Grinband, Jack , Yu, James B , Walch, Henry , Parker, Mitchell I , Shuryak, Igor , Roy, Soumyajit , Gallitto, Matthew , Horowitz, David P , McKhann, Guy M , Bruce, Jeffrey N , Ostrom, Quinn T , Neugut, Alfred I , Pike, Luke R G , Cheng, Simon K , Kachnic, Lisa A , Mehta, Minesh P , Wang, Tony J C , Minniti, Giuseppe , Siegelin, Markus D. , Kocakavuk, Emre , Ducray, François , Simonelli, Matteo , Yu, James B. , Hervey‐Jumper, Shawn L. , McKhann, Guy M. , Canoll, Peter , Ostrom, Quinn T. , Iwamoto, Fabio M., Mehta, Minesh P. , Wang, Tony J. C.

Mayo Clinic

Journal of Clinical Oncology | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-01846 | PMID 42585601 Get It

PURPOSE Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era. METHODS The Prospective Gliomas Research (PROGRES) database contains individual patient-level data from 11 prospective clinical trials or observational registries of histologically defined lower-grade 2-3 oligodendroglioma or astrocytoma. We determined the association of age (18-39 years v ≥40 years) with progression-free survival (PFS) stratified by isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) status, using log-rank tests and Cox regression models. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] database). RESULTS We identified 1,619 and 1,292 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH -wildtype tumors were more common in patients 40 years and older (38% v 5%, odds ratio: 11.3 [95% CI, 6.5 to 19.7]). Age was associated with PFS in IDH -wildtype (5-year PFS for ≥40 v 18-39 years: 6% v 24%, hazard ratio [HR], 1.74 [95% CI, 1.21 to 2.50]) but not in IDH -mutant glioma (60% v 59%, HR, 0.89 [95% CI, 0.76 to 1.05], P interaction < .001). In IDH -wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% v 28%), EGFR amplification (41% v 15%), and chromosome +7/–10 alteration (57% v 25%). In a pooled analysis of four clinical trials, age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone for IDH -mutant glioma. CONCLUSION In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.